detrusitol retard hart forðahylki 2 mg
upjohn eesv - tolterodinum l-tartrat - hart forðahylki - 2 mg
detrusitol retard hart forðahylki 4 mg
upjohn eesv - tolterodinum l-tartrat - hart forðahylki - 4 mg
dostinex tafla 0,5 mg
pfizer aps - cabergolinum inn - tafla - 0,5 mg
relpax filmuhúðuð tafla 40 mg
upjohn eesv - eletriptanum brómíð - filmuhúðuð tafla - 40 mg
tafil tafla 0,25 mg
upjohn eesv - alprazolamum inn - tafla - 0,25 mg
tafil tafla 0,5 mg
upjohn eesv - alprazolamum inn - tafla - 0,5 mg
tafil retard forðatafla 0,5 mg
upjohn eesv - alprazolamum inn - forðatafla - 0,5 mg
tafil retard forðatafla 1 mg
upjohn eesv - alprazolamum inn - forðatafla - 1 mg
pylclari
curium pet france - piflufolastat (18f) - blöðruhálskirtli - greining geislavirkja - Þetta lyf er eingöngu ætlað til greiningar. pylclari is indicated for the detection of prostate-specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high-risk pca prior to initial curative therapy,to localize recurrence of pca in patients with a suspected recurrence based on increasing serum prostate-specific antigen (psa) levels after primary treatment with curative intent. pylclari is indicated for use with positron emission tomography (pet).